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ABSTRACT
Objectives To explore the prevalence of multimorbidity 
as well as individual and combinations of long- term 
conditions (LTCs) in people with type 2 diabetes 
(T2D) attending Australian general practice, using 
electronic health record (EHR) data. We also examine 
the association between multimorbidity condition count 
(total/concordant(T2D related)/discordant(unrelated)) and 
glycaemia (glycated haemoglobin, HbA1c).
Design Cross- sectional study.
Setting Australian general practice.
Participants 69 718 people with T2D with a general 
practice encounter between 2013 and 2015 captured in 
the MedicineInsight database (EHR Data from 557 general 
practices and >3.8 million Australian patients).
Primary and secondary outcome measures Prevalence 
of multimorbidity, individual and combinations of LTCs. 
Multivariable linear regression models used to examine 
associations between multimorbidity counts and HbA1c 
(%).
Results Mean (SD) age 66.42 (12.70) years, 46.1% 
female and mean (SD) HbA1c 7.1 (1.4)%. More than 90% 
of participants with T2D were living with multimorbidity. 
Discordant conditions were more prevalent (83.4%) 
than concordant conditions (69.9 %). The three most 
prevalent discordant conditions were: painful conditions 
(55.4%), dyspepsia (31.6%) and depression (22.8%). 
The three most prevalent concordant conditions were 
hypertension (61.4%), coronary heart disease (17.1%) and 
chronic kidney disease (8.5%). The three most common 
combinations of conditions were: painful conditions and 
hypertension (38.8%), painful conditions and dyspepsia 
(23.1%) and hypertension and dyspepsia (22.7%). We 
found no associations between any multimorbidity counts 
(total, concordant and discordant) or combinations and 
HbA1c.
Conclusions Multimorbidity was common in our cohort of 
people with T2D attending Australian general practice, but 
was not associated with glycaemia. Although we did not 
explore mortality in this study, our results suggest that the 
increased mortality in those with multimorbidity and T2D 
observed in other studies may not be linked to glycaemia. 
Interestingly, discordant conditions were more prevalent 
than concordant conditions with painful conditions 
being the second most common comorbidity. Better 
understanding of the implications of different patterns of 
multimorbidity in people with T2D will allow more effective 
tailored care.
BACKGROUND
Type 2 diabetes (T2D) is recognised as 
a leading health priority associated with 
increased risk for premature mortality and is 
a global economic burden.1 Multimorbidity is 
the co- occurrence of two or more long- term 
conditions (LTCs) in an individual,2 3 which 
is the norm in T2D. It has been estimated 
that approximately 85% of those living with 
T2D have at least one other LTC.4 Multimor-
bidity amplifies the complex management of 
T2D including the challenges in managing 
higher treatment burden due to complicated 
self- management requirements as a result of 
having multiple LTCs5 and has been associ-
ated with increased mortality.6 Multimorbidity 
in those with T2D could result in reduced 
adherence to complex therapeutic regimens 
Strengths and limitations of this study
 ► This is the first study to assess the associations 
between total, concordant and discordant multimor-
bidity counts and multimorbidity combinations, and 
glycated haemoglobin (HbA1c) in people with type 2 
diabetes (T2D) in Australian general practice.
 ► The study utilised a large, national, routinely col-
lected real world general practice dataset from 557 
Australian general practices.
 ► We recognise the limitation of a cross- sectional 
study design where we did not consider the changes 
in long- term conditions (LTCs) and HbA1c over time, 
and the duration of LTCs in addition to T2D.
 ► The study relies on data entered into the electronic 
health records and therefore there is a possibility 
in under- reporting of conditions as a result of non- 
recording of diagnoses and the way each long- term 
condition is recorded which is dependent on the cli-
nicians’ recording practices.
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and poorer outcomes including suboptimal glycaemic 
management,7–9 which may underpin poor outcomes. 
Glycated haemoglobin (HbA1c) is an important clinical 
measure to consider in T2D and glycaemic management 
is a key component of clinical guidelines for people with 
T2D.
HbA1c has been used to established glycaemic targets 
and measure efficacy of T2D management and treat-
ment. It is evident that reducing HbA1c and avoiding 
hyperglycaemia results in clinical benefits including 
reduced microvascular and cardiovascular compli-
cations.9–12 Indeed, for every 1% increase in HbA1c, 
there is a 21% increase in risk of serious and costly 
complications.13
A recent systematic review examined all existing studies 
that explored associations between multimorbidity and 
any glycaemic outcomes, including HbA1c, in people 
with T2D.14 15 It identified 14 cross- sectional studies that 
showed mixed associations between multimorbidity and 
HbA1c, however, none of the studies were conducted in 
an Australian setting or population. Despite the impor-
tance of examining the impact of multimorbidity in 
people with T2D, particularly its effect on glycaemia, 
currently, there is no universally accepted measure of 
multimorbidity. However, it has been suggested that 
multiple LTCs in people with T2D should be qualitatively 
assessed as concordant or discordant.8 Concordant condi-
tions are those closely related to T2D that are more likely 
to be the focus of the same disease and management plan 
(eg, hypertension), whereas discordant conditions are 
not directly related in their pathophysiology or manage-
ment (eg, depression and cancer).
While the association between multimorbidity and 
HbA1c in people with T2D has been studied to some 
extent,14 we do not have a good understanding of the 
different patterns of multimorbidity, including concor-
dant and discordant conditions, and how they are asso-
ciated with HbA1c in T2D in Australian general practice. 
The Academy of Medical Sciences has highlighted the 
importance of increasing understanding of different 
patterns of multimorbidity internationally, including 
identifying common clusters of LTCs.16 A study has exam-
ined the prevalence of combinations of two and three 
LTCs in Australian general practice though not in people 
with T2D.17 One of the guiding principles for multimor-
bidity in the Royal Australian College of General Prac-
titioner (RACGP) guidelines for T2D management was 
to be aware of common comorbidities with T2D.18 We, 
therefore, explored the prevalence of multimorbidity 
including the prevalence of individual, concordant and 
discordant LTCs and condition combinations, in a cohort 
of people with T2D attending Australian general practice 
using MedicineInsight which routinely collects electronic 
health record (EHR) data.19 We also examined the asso-
ciations between multimorbidity count (total, concordant 
and discordant) and HbA1c.
METHODS
Study design and participants
This cross- sectional study was conducted using data from 
MedicineInsight. This national database is managed by 
National Prescribing Service (NPS) MedicineWise and 
was established to support quality improvement in Austra-
lian general practice and postmarket surveillance of 
medicines.19 MedicineInsight extracts and collates longi-
tudinal, deidentified patient health records, including 
demographics, encounters (excluding progress notes), 
diagnoses, prescriptions and pathology tests from general 
practice clinical information systems (CIS) Medical 
Director and Best Practice. Data extraction for our study 
was 1 September 2015, and included data from 557 
Australian general practices, located in every Australian 
state and territory, and represented more than 3.8 million 
patient records.19
Patients aged ≥18 years that had ever had a recorded 
diagnosis of T2D, marked as an active patient20 (defined 
as having at least three encounters recorded over a 2- year 
period [between 1 September of 2013 and 2015]) at 1 
September 2015 were included in this study. This Medi-
cineInsight dataset consisted of 105 135 people with T2D 
during this time period. Of these, 35 417 did not have 
HbA1c data recorded and were excluded from the study. 
We, therefore, analysed data from 69 718 people.
Procedures
The included LTCs were based on previous published 
literature on multimorbidity.21 These consist of 43 indi-
vidual LTCs where nine conditions were concordant with 
diabetes and the remainder discordant with diabetes 
(online supplemental table S1). Almost all LTCs were 
defined by composite definitions. We coded the condi-
tions based on data entered in the reason for visit, reason 
for prescription or medical history fields and undertook 
an additional search to capture diagnoses recorded in 
free text. All codes were carefully reviewed by at least 
two expert academic general practitioners. In cases of 
uncertainty, a consensus was reached after discussion 
with a third expert. We included LTCs ever recorded in 
the MedicineInsight database. We created three new vari-
ables: the total number of LTCs, the number of concor-
dant only conditions and number of discordant only 
conditions.
Clinical outcome
The outcome measure of interest was HbA1c (%) and 
we used the most recently recorded HbA1c that has ever 
been in the participant’s EHR, treated as a continuous 
variable. Results of HbA1c tests were identified using text 
searches on pathology test names (eg, HbA1c test may 
be recorded as HbA1c or glycated HbA1c or Haemo-
globin A1c) and Logical Observation Identifiers Names 
and Codes, a code for a pathology test that is provided 
by pathology laboratories for our previous studies under-
taken using this dataset.22–24
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Statistical analysis
Descriptive statistics were used to summarise overall char-
acteristics of the participants including age, sex, smoking 
status, HbA1c, use of diabetes medication (number of 
non- insulin antidiabetic medications, insulin use only 
or both), and socioeconomic status measured by Socio- 
Economic Indexes for Areas (SEIFA) scores presented 
in deciles.25 The SEIFA scores for each participant postal 
code are calculated by summarising attributes of the 
population collected through Australia’s national census, 
such as income, educational attainment, employment 
and occupation. These scores are grouped into deciles 
where decile one represents the most disadvantaged and 
decile 10 represents the least disadvantaged. The counts 
and proportions of LTCs concordant and discordant 
with diabetes were also summarised. Summaries include 
frequencies and percentages for categorical data, means 
and SD for normally distributed continuous data and 
medians and IQR for skewed continuous data. χ2 and 
t- tests were used to compare differences between people 
with T2D who had multiple LTCs and people with T2D 
only.
Multivariable mixed- effects linear regression models 
were used to examine the association between HbA1c 
and each of the multimorbidity counts (total; total of 
concordant conditions; total of discordant conditions) 
controlling for age, sex, SEIFA decile, smoking status and 
number of diabetes medications. Duration of diabetes was 
originally included in the adjusted model but was removed 
due to multicollinearity with age. The model without the 
inclusion of diabetes duration resulted in a better fit of 
the data with variance inflation factors reduced to within 
acceptable limits and improved stability.
In a secondary analysis, we selected the LTCs in our 
multimorbidity count that occur with a prevalence of more 
than 1% in this cohort. For each of the LTCs identified, 
multivariable mixed- effects linear regression models were 
used to examine the association with HbA1c, adjusting 
for age, sex, SEIFA decile, smoking status and number of 
diabetes medication. Consistent with the RACGP guide-
lines for multimorbidity in people with T2D, we also 
selected the top 10 most prevalent LTCs and examined all 
possible combinations of two conditions and their associ-
ation with HbA1c using multivariable mixed- effects linear 
regression models.
In all the regression models, we treated the confounding 
factors as fixed effects and the general practice as a 
random effect to allow for the correlation of HbA1c 
within each practice. All analyses were carried out using 
STATA V.15.1 (StataCorp).
Sensitivity analysis
In the sensitivity analysis, we categorised our study partic-
ipants by the general treatment target of HbA1c (those 
with HbA1c >7% and≤7%).26 We explored the associ-
ation between HbA1c and each of the multimorbidity 
counts using multivariable mixed- effects linear regression 
models in each of the HbA1c groups. We adjusted for the 
same covariates as the main analysis described above.
RESULTS
In this cohort of 69 718 people with T2D attending 
Australian general practice the mean (SD) age was 66.42 
(12.70) and 46.1% were female. In our study, multimor-
bidity was present in 63 326 (90.8%). Table 1 describes 
the overall characteristics of our study participants and 
compares the characteristics between those with T2D and 
multimorbidity and those with T2D only. The characteris-
tics of those with T2D and multimorbidity and those with 
T2D only were similar.
The prevalence of individual LTCs included in our 
multimorbidity total, concordant and discordant counts 
are shown in table 2. In our study cohort, 48 733 (69.9%) 
people had at least one concordant condition and 58 151 
(83.4%) had at least one discordant condition in addition 
to T2D. The most prevalent concordant condition was 
hypertension (61.4%) while painful conditions (55.4%) 
was the most prevalent discordant condition.
Table 3 shows the mean difference in HbA1c between 
participants with different multimorbidity counts where 
participants with T2D only were the reference group. For all 
increasing counts of multimorbidity (total, concordant and 
discordant) there were no association with HbA1c.
In the sensitivity analysis, when we categorised the study 
participants into HbA1c of >7% and≤7% the results for the 
effect of all multimorbidity counts on HbA1c were similar to 
the main analysis, where there was no evidence to support 
any associations between multimorbidity counts and HbA1c 
(online supplemental table S2).
Table 4 shows the association between individual LTCs that 
had a prevalence of greater than 1% in our study population 
and HbA1c. All concordant conditions and 23 discordant 
conditions met this criterion. We did not find any associations 
between each of the individual LTCs (prevalence 1%) and 
HbA1c, with the exception of coronary heart disease.
Figure 1 shows the prevalence of all possible combinations 
of two conditions of the top 10 most prevalent conditions in 
our cohort. The most prevalent combinations were painful 
conditions and hypertension (38.8%), painful conditions 
and dyspepsia (23.1%), hypertension and dyspepsia (22.7%), 
painful conditions and depression (15.8%), and hyperten-
sion and depression (14.9%).
Table 5 shows the association between combinations of 
two LTCs from the top 10 most prevalent conditions in our 
cohort and HbA1c. We found associations between slightly 
higher HbA1c and coronary heart disease in combination 
with hypertension, depression, anxiety and psoriasis/eczema. 
We did not find associations between any of the other combi-
nations and HbA1c.
DISCUSSION
In this study, comprising of nearly 70 000 people with T2D 
regularly attending Australian general practice, 90.8% of 
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people were living with at least one other LTC in addi-
tion to T2D. Discordant conditions (such as painful 
conditions, dyspepsia, depression or psoriasis) were more 
prevalent (83.4%) than concordant conditions (69.9%). 
Our findings showed no evidence of an association 
between any counts of multimorbidity (total, concordant 
Table 1 Characteristics of participants with type 2 diabetes (T2D)
Demographics Total N=69 718 T2D only N=6392
T2D + ≥1 chronic 
condition N=63 326 P value
Age, years, mean (SD) 66.42 (12.70) 66.41 (12.53) 66.42 (12.71) 0.948
Female, n(%) 32 137 (46.1) 3017 (47.2) 29 120 (46.0) 0.172
Missing 29 (0.0) 3 (0.1) 26 (0.0)
SEIFA deciles, n(%)     0.082
  Decile 1—most deprived 6223 (8.9) 606 (9.5) 5617 (8.9)
  Decile 2 7924 (11.4) 729 (11.4) 7195 (11.4)
  Decile 3 5367 (7.7) 449 (7.0) 4918 (7.8)
  Decile 4 7508 (10.8) 696 (10.9) 6812 (10.8)
  Decile 5 7343 (10.5) 657 (10.3) 6686 (10.6)
  Decile 6 8169 (11.7) 801 (12.5) 7368 (11.6)
  Decile 7 6344 (9.1) 579 (9.1) 5765 (9.1)
  Decile 8 6192 (8.9) 588 (9.2) 5604 (8.9)
  Decile 9 7630 (10.9) 676 (10.6) 6954 (11.0)
  Decile10—least deprived 6402 (9.2) 550 (8.6) 5852 (9.2)
  Missing 616 (0.9) 61 (1.0) 555 (0.9)
Smoking status, n(%)     0.912
  Current/previous 31 608 (45.3) 2917 (45.6) 28 691 (45.3)
  Never smoked 32 792 (47.0) 3004 (47.0) 29 788 (47.0)
  Missing 5318 (7.6) 471 (7.4) 4847 (7.7)
HbA1c, mmol/mol, mean (SD) 54 (16) 54 (16) 54 (16) 0.672
HbA1c, %, mean (SD) 7.1 (1.4) 7.1 (1.4) 7.1 (1.4) 0.672
HbA1c, %, n(%)     0.449
  ≤7 41 265 (59.2) 3755 (58.7) 37 510 (59.2)
  >7 28 453 (40.8) 2637 (41.3) 25 816 (40.8)
Diabetes medication, n(%)     0.278
  No medication 19 556 (28.1) 1734 (27.1) 17 822 (28.1)
  1 antidiabetic medication 23 762 (34.1) 2225 (34.8) 21 537 (34.0)
  2 antidiabetic medications 12 879 (18.5) 1158 (18.1) 11 721 (18.5)
  3 antidiabetic medications 3037 (4.4) 264 (4.1) 2773 (4.4)
  ≥4 antidiabetic medications 244 (0.4) 25 (0.4) 219 (0.4)
  Insulin use only 2930 (4.2) 281 (4.4) 2649 (4.2)
  Insulin +antidiabetic medication(s) 7310 (10.5) 705 (11.0) 6605 (10.4)
No of chronic conditions, n(%)     n/a
  T2D only 6392 (9.2) 6392 (100) n/a
  T2D+1 chronic condition 8497 (12.2) n/a 8497 (13.4)
  T2D+2 chronic condition 10 614 (15.2) n/a 10 614 (16.8)
  T2D+3 chronic condition 10 516 (15.1) n/a 10 516 (16.6)
  T2D +≥4 chronic conditions 33 699 (48.3) n/a 33 699 (53.2)
Concordant conditions only, n(%) 5175 (7.4) n/a 5175 (8.2)
Discordant conditions only, n(%) 14 593 (20.9) n/a 14 593 (23.0)
HbA1c, glycated haemoglobin; n/a, not applicable; SEIFA, Socio- Economic Indexes for Areas.
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and discordant) and HbA1c. The presence of individual 
and combinations of LTCs in addition to T2D were not 
associated with HbA1c, with the exception of coronary 
heart disease.
Our prevalence findings of multimorbidity add to 
existing literature where it has been estimated that 
approximately 85% of those living with T2D have at least 
one other LTC.4 The prevalence of individual LTCs iden-
tified in our study align with a recent study that explored 
multimorbidity in people with T2D across the UK and 
Taiwan.6 This is in spite of the study examining commu-
nity cohorts of people with T2D rather than people 
attending general practice. This confirms how commonly 
people are burdened by multimorbidity and that that 
this is likely to impact on the already complex nature 
of T2D management. Currently, the Royal Australia 
College of General Practitioners (RACGP) guidelines 
for T2D acknowledge that clinical guidance regarding 
the management of comorbid conditions is currently 
lacking or sparse.18 However, one guiding principle was 
to be aware of common comorbidities with diabetes. Our 
findings regarding the most common LTCs associated, 
either singly or in combination, with T2D have direct 
implications for this. We showed that for concordant 
conditions, hypertension was the most common condi-
tion, and following that was coronary artery disease. It 
should be noted that the treatment and prevention of 
these conditions with the exception of atrial fibrillation 
and partially heart failure have been incorporated into 
the diabetes guidelines.18 However, importantly, discor-
dant conditions were more prevalent than concordant 
conditions in our study, where painful conditions was 
the most common comorbidity. Although the RACGP 
guideline recommends that clinicians should be aware of 
commonly occurring conditions, another guiding prin-
ciple is to set treatment priorities with the patient.18 It is 
important to focus on outcomes and co- occurring condi-
tions that matter most to the individual because shared 
decision making is vital to ensure care is tailored to the 
individual.8 27–29 Given how common painful conditions 
are, patients may prioritise therapeutic interventions 
differently, for example pain relief being considered 
above diabetes management.
Table 2 Prevalence of individual multimorbid conditions in 
participants with type 2 diabetes
Presence of chronic conditions 
concordant with type 2 diabetes, n(%)
N=69 718
At least one chronic condition 
concordant with diabetes
48 733 (69.9)
Hypertension 42 812 (61.4)
Coronary heart disease 11 953 (17.1)
Chronic kidney disease 5919 (8.5)
Atrial fibrillation 5318 (7.3)
Stroke/TIA 4730 (6.8)
Heart failure 4410 (6.3)
Diabetic retinopathy 2266 (3.3)
Peripheral vascular disease 1945 (2.8)
Diabetic neuropathy 1117 (1.6)
Presence of chronic conditions 
discordant with type 2 diabetes, n(%)
n=69 718
At least one chronic condition 
discordant with diabetes
58 151 (83.4)
Painful conditions 38 645 (55.4)
Dyspepsia 22 022 (31.6)
Depression 15 926 (22.8)
Anxiety 14 262 (20.5)
Psoriasis/eczema 14 037 (20.1)
Cancer 12 733 (18.3)
Asthma 10 276 (14.7)
Thyroid disorders 7613 (10.9)
Diverticular disease 6039 (8.7)
COPD 5521 (7.9)
Constipation 5162 (7.4)
Chronic liver disease 4864 (7.0)
Osteoporosis 4567 (6.6)
Glaucoma 3102 (4.5)
Migraine 2643 (3.8)
Rheumatoid arthritis and other 
connective tissue disorders
2622 (3.8)
Dementia 2247 (3.2)
Schizophrenia/bipolar disorder 2198 (3.2)
Irritable bowel syndrome 1540 (2.2)
Alcohol problems 1447 (2.1)
Viral hepatitis 815 (1.2)
Epilepsy 754 (1.1)
Parkinson’s disease 628 (0.9)
Chronic sinusitis 597 (0.9)
Meniere’s disease 520 (0.8)
Inflammatory bowel disease 515 (0.7)
Polycystic ovary 488 (0.7)
Other psychoactive substance misuse 463 (0.7)
Continued
Bronchiectasis 448 (0.6)
Pernicious anaemia 330 (0.5)
Endometriosis 280 (0.4)
Chronic fatigue syndrome 168 (0.2)
Prostate disorders 154 (0.2)
Anorexia/bulimia 148 (0.2)
Multiple sclerosis 114 (0.2)
COPD, chronic obstructive pulmonary disease; TIA, transient 
ischaemic attack.
Table 2 Continued
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We also contribute to the understanding of patterns of 
multimorbidity in people with T2D through exploring 
the most common combinations of two LTCs. Our LTC 
combinations findings further confirms the significance 
of discordant conditions in T2D. We showed that painful 
conditions, dyspepsia, depression, psoriasis/eczema, 
anxiety, cancer and one concordant condition, hyperten-
sion, were present in the majority of the most common 
combinations. While managing concordant conditions, 
namely cardiovascular diseases, are important, it should 
not overshadow efforts to address discordant conditions 
in people with T2D.
Our results add to the findings of a recent systematic 
review which highlighted mixed associations between 
multimorbidity and HbA1c in T2D.14 It has been well 
established that achieving HbA1c targets is a key compo-
nent of T2D management and clinical guidelines and is 
important in reducing downstream complications and 
risk of mortality.30 Our findings contrast with a recent 
study of diabetes and multimorbidity using data from UK 
Biobank and the Taiwan National Diabetes Care Manage-
ment Programme which suggested that increasing total 
and discordant multimorbidity counts were associated 
with lower HbA1c and increased mortality in both data-
sets.6 Our findings show that coronary heart disease 
was associated with slightly higher HbA1c both when 
considered as an individual condition and in different 
combinations with hypertension, depression, anxiety 
and psoriasis/eczema. Although the degree of observed 
differences in HbA1c noted in our study (ranging from 
Table 3 Multivariable linear regression model: relationship between HbA1c(%) and multimorbidity in participants with type 2 
diabetes
Predictor variables
Non- adjusted Adjusted*
Mean 
difference in 
HbA1c (SE) 95% CI P value
Mean 
difference in 
HbA1c (SE) 95% CI P value
Categories of diabetes and multimorbidities
Diabetes present and no chronic conditions (reference)
  Diabetes present and one chronic 
condition
−0.01 (0.02) −0.05 to 0.04 0.757 −0.01 (0.02) −0.05 to 0.04 0.685
  Diabetes present and two chronic 
conditions
−0.02 (0.02) −0.07 to 0.02 0.348 −0.02 (0.02) −0.06 to 0.02 0.341
  Diabetes present and three chronic 
conditions
−0.01 (0.02) −0.06 to 0.03 0.549 0.00 (0.02) −0.04 to 0.04 0.968
  Diabetes present and four or more 
chronic conditions
0.00 (0.02) −0.04 to 0.04 0.912 −0.01 (0.02) −0.04 to 0.03 0.731
Categories of diabetes and concordant conditions
Diabetes present and no chronic conditions (reference)
  Diabetes present and one concordant 
condition
0.01 (0.01) −0.02 to 0.03 0.701 0.00 (0.01) −0.02 to 0.03 0.799
  Diabetes present and two concordant 
conditions
0.02 (0.02) −0.01 to 0.05 0.250 0.02 (0.02) −0.01 to 0.05 0.150
  Diabetes present and three 
concordant conditions
0.00 (0.02) −0.04 to 0.05 0.947 −0.01 (0.02) −0.05 to 0.03 0.556
  Diabetes present and four or more 
concordant conditions
0.05 (0.03) −0.01 to 0.10 0.100 0.04 (0.03) −0.02 to 0.09 0.175
Categories of diabetes and discordant conditions
Diabetes present and no chronic conditions (reference)
  Diabetes present and one discordant 
condition
−0.03 (0.02) −0.06 to 0.01 0.159 −0.03 (0.02) −0.06 to 0.01 0.099
  Diabetes present and two discordant 
conditions
−0.03 (0.02) −0.07 to 0.00 0.077 −0.02 (0.02) −0.06 to 0.01 0.223
  Diabetes present and three 
discordant conditions
−0.01 (0.02) −0.05 to 0.03 0.622 −0.01 (0.02) −0.05 to 0.02 0.508
  Diabetes present and four or more 
discordant conditions
0.00 (0.02) −0.03 to 0.04 0.838 0.00 (0.02) −0.03 to 0.03 0.886
*Adjusting for age, sex, SEIFA, smoking status, and number of diabetes medication. All co- variates were treated as fixed effects and the 
general practice as a random effect to allow for the correlation of HbA1c within each practice.
HbA1c, glycated haemoglobin; SEIFA, Socio- Economic Indexes for Areas.
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Table 4 Multivariable linear regression model: relationship between HbA1c(%) and the presence of individual conditions 
(prevalence >1%) in participants with type 2 diabetes (T2D)
Predictor variables
Prevalence 
N(%)
Non- adjusted Adjusted*
Mean difference 
in HbA1c (SE) 95% CI P value
Mean difference 
in HbA1c (SE) 95% CI P value
Concordant conditions
T2D only (reference)
  Hypertension 42 812 (61.4) 0.01 (0.01) −0.01 to 0.03 0.364 0.01 (0.01) −0.01 to 0.03 0.336
  Coronary heart 
disease
11 953 (17.1) 0.03 (0.02) 0.00 to 0.06 0.022 0.03 (0.01) 0.00 to 0.05 0.040
  Chronic kidney 
disease
5919 (8.5) 0.01 (0.02) −0.03 to 0.05 0.745 −0.01 (0.02) −0.05 to 0.02 0.456
  Atrial fibrillation 5318 (7.3) 0.01 (0.02) −0.03 to 0.05 0.567 0.00 (0.02) −0.04 to 0.04 0.907
  Stroke/TIA 4730 (6.8) −0.01 (0.02) −0.05 to 0.03 0.692 0.00 (0.02) −0.42 to 0.04 0.919
  Heart failure 4410 (6.3) 0.02 (0.02) −0.02 to 0.07 0.333 0.01 (0.02) −0.03 to 0.05 0.622
  Diabetic retinopathy 2266 (3.3) −0.02 (0.03) −0.08 to 0.04 0.547 0.00 (0.03) −0.06 to 0.06 0.996
  Peripheral vascular 
disease
1945 (2.8) 0.05 (0.03) −0.02 to 0.11 0.151 0.02 (0.03) −0.05 to 0.08 0.509
  Diabetic neuropathy 1117 (1.6) −0.01 (0.04) −0.10 to 0.07 0.763 0.01 (0.04) −0.07 to 0.09 0.892
Discordant conditions
T2D only (reference)
  Painful conditions 38 645 (55.4) 0.01 (0.01) −0.04 to 0.01 0.211 −0.02 (0.01) −0.04 to 0.00 0.122
  Dyspepsia 22 022 (31.6) 0.00 (0.01) −0.02 to 0.02 0.954 0.00 (0.01) −0.02 to 0.03 0.746
  Depression 15 926 (22.8) 0.00 (0.01) −0.03 to 0.80 0.801 −0.01 (0.01) −0.03 to 0.02 0.600
  Anxiety 14 262 (20.5) 0.00 (0.01) −0.02 to 0.03 0.772 −0.01 (0.01) −0.03 to 0.02 0.621
  Psoriasis/eczema 14 037 (20.1) 0.02 (0.01) −0.01 to 0.04 0.193 0.02 (0.01) −0.01 to 0.04 0.130
  Cancer 12 733 (18.3) 0.01 (0.01) −0.01 to 0.04 0.319 0.00 (0.01) −0.02 to 0.03 0.704
  Asthma 10 276 (14.7) −0.01 (0.02) −0.04 to 0.02 0.412 −0.02 (0.01) −0.05 to 0.01 0.219
  Thyroid disorders 7613 (10.9) 0.02 (0.02) −0.02 to 0.05 0.309 0.00 (0.02) −0.03 to 0.03 0.961
  Diverticular disease 6039 (8.7) 0.02 (0.19) −0.02 to 0.06 0.279 0.02 (0.02) −0.02 to 0.05 0.366
  COPD 5521 (7.9) 0.02 (0.02) −0.02 to 0.06 0.315 0.02 (0.02) −0.02 to 0.06 0.273
  Constipation 5162 (7.4) 0.02 (0.02) −0.02 to 0.06 0.339 0.01 (0.02) −0.03 to 0.05 0.524
  Chronic liver 
disease
4864 (7.0) 0.03 (0.02) −0.01 to 0.08 0.129 0.02 (0.02) −0.02 to 0.06 0.222
  Osteoporosis 4567 (6.6) 0.00 (0.02) −0.04 to 0.05 0.882 0.01 (0.02) −0.03 to 0.05 0.761
  Glaucoma 3102 (4.5) 0.05 (0.03) 0.00 to 0.11 0.038 0.03 (0.02) −0.02 to 0.08 0.235
  Rheumatoid 
arthritis and other 
connective tissue 
disorders
2643 (3.8) −0.01 (0.03) −0.06 to 0.05 0.8 0.01 (0.03) −0.04 to 0.07 0.597
  Migraine 2622 (3.8) −0.03 (0.03) −0.09 to 0.03 0.305 −0.01 (0.03) −0.07 to 0.04 0.575
  Dementia 2247 (3.2) 0.05 (0.03) −0.01 to 0.11 0.09 0.03 (0.03) −0.02 to 0.09 0.255
  Schizophrenia/ 
bipolar disorder
2198 (3.2) −0.01 (0.03) −0.08 to 0.05 0.655 −0.01 (0.03) −0.07 to 0.05 0.694
  Irritable bowel 
syndrome
1540 (2.2) −0.01 (0.04) −0.08 to 0.06 0.756 −0.01 (0.03) −0.08 to 0.05 0.676
  Alcohol problem 1447 (2.1) 0.00 (0.04) −0.07 to 0.08 0.96 0.00 (0.04) −0.07 to 0.07 0.974
  Viral hepatitis 815 (1.2) 0.02 (0.05) −0.08 to 0.12 0.689 0.04 (0.05) −0.05 to 0.13 0.393
  Epilepsy 754 (1.1) 0.09 (0.05) −0.02 to 0.19 0.108 0.08 (0.05) −0.01 to 0.18 0.082
*Adjusting for age, sex, SEIFA, smoking status, and number of diabetes medication. All covariates were treated as fixed effects and the 
general practice as a random effect to allow for the correlation of HbA1c within each practice.
COPD, chronic obstructive pulmonary disease; HbA1c, glycated haemoglobin; TIA, transient ischaemic attack.
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0.03% to 0.08%) and the recent UK and Taiwan study 
are very small and are not likely to be clinically signifi-
cant despite being statistically significant. Our findings 
could possibly be linked to the higher healthcare utili-
sation31 and better quality of care32 seen in people with 
LTCs, hence leading to more opportunities for clinical 
interventions leading to achieving HbA1c targets. This is 
further highlighted by our study cohort being relatively 
healthy with good glycaemic control (mean (SD) HbA1c 
7.1 (1.4)%), similar to the Australian general treatment 
target of 7%.26 Moreover, 28% of our study cohort was 
not on any diabetes medication further highlighting our 
generally healthy cohort of participants with T2D.
To the best of our knowledge, this is the first study to 
assess the effects of total, concordant and discordant 
multimorbidity counts on HbA1c in people with T2D in 
Australian general practice. The strength of the study 
includes using a large, national, routinely collected real 
world general practice dataset from 557 Australian general 
practices. We recognise the limitation of a cross- sectional 
study design where we did not consider the temporality of 
LTCs and HbA1c, and the duration of LTCs in addition to 
diabetes. Furthermore, when coding for LTCs we did not 
test inter- observer reliability. A limitation to note is that 
a relatively high number of participants were excluded 
from the study as they didn’t have recorded HbA1c, 
and these participants may not be similar to those with 
recorded HbA1c. HbA1c was measured at various sites 
meaning possible variations due to measurement error at 
different sites could have affected the results of the study. 
We only included active patients defined as having at least 
three encounters recorded over a 2- year period and this 
could be a potential limitation where those excluded may 
have differences in baseline characteristics. We also did 
not conduct a sample size calculation in this retrospective 
observational study. As this was a dataset using routinely 
collected real world clinical data, a limitation of our study 
is that some important lifestyle variables such as physical 
activity were not available to be included in the anal-
yses. Another limitation of the study is that the quality of 
MedicineInsight data is dependent on the accuracy and 
completeness of data recorded in general practice CISs, 
in fields that can be extracted or in a useable format. To 
improve the quality of the data, selection criteria for both 
patients and practices, and extensive data cleaning proce-
dures are applied.19 For privacy reasons, MedicineInsight 
does not include data from progress notes, which may 
contain further clinical information. As such, this may 
result in underestimating the number of conditions expe-
rienced by people with T2D. In 2018, MedicineInsight 
published a report33 comparing their dataset in terms of 
the prevalence of LTCs captured to the Australian Bureau 
of Statistics (ABS) data, which is based on self- report,4 
and data from the Bettering the Evaluation and Care of 
Health (BEACH) study, which is prospectively collected 
by general practitioners recording patient encounters on 
structured paper- based recording sheets.34 It is reported 
that the prevalence of chronic conditions in the Medi-
cineInsight data align with ABS data or are slightly higher. 
When compared with data from the BEACH study, the 
MedicineInsight conditions, rates per 100 encounters 
were slightly lower. This may be the case because condi-
tions that have been previously entered into EHR might 
not be re- entered by the clinicians into the relevant 
CIS fields used for analysis (reason for visit, reason for 
prescription or medical history fields), or data may be 
entered into the progress notes (which are not accessible 
to MedicineInsight). Furthermore, in the BEACH study, 
general practitioners were asked to provide complete 
information on structured paper- based recording sheets 
for a given encounter. Despite our efforts to compensate 
for the challenges of the MedicineInsight dataset by using 
a panel of expert academic general practitioners coding 
for conditions in multiple fields with additional searches in 
free text fields there is still a possibility in under- reporting 
of conditions as a result of non- recording of diagnoses 
and the way each LTC is recorded which is dependent 
on the clinicians’ recording practices. Furthermore, it is 
possible that some patients captured in the dataset may 
have performed chronic disease screening elsewhere 
because in Australia, people are free to attend other and 
multiple general practice clinics although the majority 
tend to stay with one practice. Despite this, the prevalence 
Figure 1 The presence of combinations of top 10 most 
prevalent conditions in participants with type 2 diabetes.
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Table 5 Multivariable linear regression model: relationship between HbA1c (%) and the presence of combinations of top 10 
most prevalent conditions in participants with type 2 diabetes (T2D)
Predictor variables
Prevalence N 
(%)
Non- adjusted Adjusted*
Mean 
difference in 
HbA1c (SE) 95% CI P value
Mean 
difference in 
HbA1c (SE) 95% CI P value
Concordant conditions
T2D only (reference)
Hypertension+painful conditions 27 063 (38.8) −0.01 (0.01) −0.03 to 0.02 0.615 −0.01 (0.01) −0.03 to 0.01 0.399
Painful conditions+dyspepsia 16 117 (23.1) −0.01 (0.01) −0.04 to 0.01 0.325 −0.01 (0.01) −0.03 to 0.02 0.674
Hypertension+dyspepsia 15 827 (22.7) 0.01 (0.01) −0.02 to 0.03 0.502 0.01 (0.01) −0.01 to 0.03 0.413
Painful conditions+depression 11 046 (15.8) 0.00 (0.01) −0.03 to 0.03 0.907 −0.01 (0.01) −0.03 to 0.02 0.675
Hypertension+depression 10 369 (14.9) 0.00 (0.02) −0.03 to 0.03 0.791 0.01 (0.01) −0.03 to 0.02 0.693
Painful conditions+psoriasis/
eczema
10 297 (14.8) 0.01 (0.02) −0.02 to 0.04 0.494 0.01 (0.01) −0.02 to 0.04 0.630
Painful conditions + anxiety 10 291 (14.8) −0.01 (0.02) −0.04 to 0.02 0.558 −0.02 (0.01) −0.04 to 0.01 0.260
Hypertension+psoriasis/ eczema 9977 (14.3) 0.02 (0.02) −0.01 to 0.05 0.220 0.02 (0.01) 0.00 to 0.05 0.087
Hypertension+anxiety 9655 (13.9) 0.01 (0.02) −0.02 to 0.04 0.557 0.01 (0.01) −0.02 to 0.04 0.559
Hypertension+cancer 9268 (13.3) 0.02 (0.02) −0.01 to 0.05 0.154 0.01 (0.02) −0.01 to 0.04 0.443
Hypertension+coronary heart 
disease
8853 (12.7) 0.03 (0.02) 0.00 to 0.06 0.050 0.03 (0.02) 0.00 to 0.06 0.025
Painful conditions+cancer 8645 (12.4) 0.02 (0.02) −0.02 to 0.05 0.299 0.01 (0.02) −0.02 to 0.04 0.702
Painful conditions+coronary heart 
disease
8066 (11.6) 0.02 (0.02) −0.01 to 0.06 0.191 0.02 (0.02) −0.01 to 0.05 0.260
Depression+anxiety 7778 (11.2) −0.01 (0.02) −0.04 to 0.03 0.692 −0.02 (0.02) −0.05 to 0.01 0.184
Painful conditions+asthma 7213 (10.4) −0.02 (0.02) −0.06 to 0.01 0.256 −0.03 (0.02) −0.07 to 0.00 0.048
Dyspepsia+depression 7139 (10.2) 0.01 (0.02) −0.02 to 0.05 0.450 0.01 (0.02) −0.02 to 0.05 0.386
Dyspepsia+anxiety 6927 (9.9) 0.02 (0.02) −0.01 to 0.06 0.282 0.01 (0.02) −0.02 to 0.05 0.446
Hypertension+asthma 6835 (9.8) 0.00 (0.02) −0.04 to 0.03 0.862 −0.01 (0.02) −0.05 to 0.02 0.452
Dyspepsia+psoriasis/eczema 6558 (9.4) 0.02 (0.02) −0.01 to 0.06 0.242 0.02 (0.02) −0.01 to 0.06 0.169
Dyspepsia+coronary heart 
disease
5447 (7.8) 0.04 (0.02) 0.00 to 0.08 0.051 0.04 (0.02) 0.00 to 0.07 0.051
Hypertension+thyroid disorders 5258 (7.5) 0.03 (0.02) −0.01 to 0.07 0.172 0.01 (0.02) −0.03 to 0.04 0.723
Dyspepsia+cancer 5214 (7.5) 0.02 (0.02) −0.02 to 0.06 0.364 0.02 (0.02) −0.02 to 0.06 0.366
Painful conditions+thyroid 
disorders
5046 (7.2) 0.00 (0.02) −0.04 to 0.04 0.953 −0.02 (0.02) −0.06 to 0.02 0.403
Dyspepsia+asthma 4780 (6.9) −0.01 (0.02) −0.06 to 0.03 0.533 −0.02 (0.02) −0.06 to 0.02 0.318
Depression+psoriasis/eczema 4363 (6.3) −0.01 (0.02) −0.05 to 0.04 0.800 −0.01 (0.02) −0.06 to 0.03 0.498
Anxiety+psoriasis/eczema 4343 (6.2) 0.00 (0.02) −0.04 to 0.04 0.889 0.00 (0.02) −0.05 to 0.04 0.839
Depression+asthma 3610 (5.2) −0.02 (0.02) −0.07 to 0.03 0.477 −0.03 (0.02) −0.08 to 0.01 0.173
Psoriasis/eczema+cancer 3293 (4.7) 0.04 (0.03) −0.01 to 0.09 0.117 0.03 (0.02) −0.02 to 0.07 0.275
Dyspepsia+thyroid disorders 3193 (4.6) 0.05 (0.03) 0.00 to 0.10 0.068 0.03 (0.02) −0.02 to 0.07 0.268
Anxiety+asthma 3144 (4.5) −0.04 (0.03) −0.09 to 0.15 0.169 −0.05 (0.02) −0.10 to 0.00 0.044
Depression+cancer 3126 (4.5) 0.03 (0.03) −0.02 to 0.09 0.206 0.01 (0.02) −0.04 to 0.06 0.721
Depression+coronary heart 
disease
3115 (4.5) 0.08 (0.03) 0.03 to 0.14 0.001 0.08 (0.02) 0.03 to 0.12 0.003
Cancer+coronary heart disease 3106 (4.5) 0.06 (0.03) 0.01 to 0.11 0.027 0.05 (0.02) 0.00 to 0.10 0.059
Psoriasis/eczema+asthma 3103 (4.5) −0.03 (0.03) −0.09 to 0.02 0.203 −0.04 (0.02) −0.08 to 0.01 0.147
Psoriasis/eczema+coronary heart 
disease
3059 (4.4) 0.06 (0.03) 0.01 to 0.11 0.031 0.05 (0.00) 0.00 to 0.10 0.037
Anxiety+cancer 3057 (4.4) 0.06 (0.03) 0.01 to 0.11 0.026 0.04 (0.02) −0.01 to 0.09 0.130
Anxiety+coronary heart disease 2977 (4.3) 0.08 (0.03) 0.02 to 0.13 0.005 0.06 (0.03) 0.01 to 0.11 0.014
Continued
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of multimorbidity and LTCs identified in our study align 
with a recent study that explored multimorbidity in T2D 
using community cohorts in the UK and Taiwan.6 This 
supports the validity of the NPS MedicineInsight dataset 
in capturing LTC prevalence in the community. Limita-
tions also exist in regards to the current infrastructure 
and standards of EHRs. Currently, there are still no 
nationally agreed and implemented standards for the 
EHR, particularly for data structure, universally accepted 
systems of classification and terminology, and consistent 
data items with clear definitions.35 Furthermore, there is 
no minimum requirement for the types of patient data 
that should be collected at every patient consultation that 
could form a standardised minimum dataset. Although 
these limitations are highlighted, they also pose as 
important findings. With the increasing interest and use 
of routinely collected data in research, quality improve-
ment and data evaluation, our study highlights important 
issues of data quality that must be addressed in the future. 
Datasets using routinely collected data will need further 
validation and perhaps data linkage through combina-
tion with other data sources, could enhance their value 
in research studies.
While our current study did not specifically explore 
mortality, our results suggest that there is a need for future 
research to examine other factors independent of HbA1c 
that contribute to the increased mortality seen in people 
with multimorbidity and T2D14 and investigate how 
people with T2D and their health professionals approach 
glycaemic management and targets in the context of 
multimorbidity. Patient- reported outcome measures such 
as quality of life, patient reported health and function 
may also be important to consider, however, these are not 
incorporated in the EHR. Linkage of MedicineInsight 
data to hospital and mortality datasets to explore health 
outcomes for people with multimorbidity and T2D is 
warranted. Improving our understanding of the biology 
or healthcare delivery approaches that are contributing 
to the effects of multimorbidity may benefit clinicians in 
tailoring care for the needs of this complex population of 
people with T2D. Gaining a greater understanding of the 
implications of different patterns of multimorbidity will 
also be important.
CONCLUSION
In approximately 70 000 people with T2D in Australian 
general practice, we have demonstrated that most people 
(>90%) with T2D live with multimorbidity and that for 
over 80% the comorbidity was discordant in nature. 
Importantly while hypertension was the most common 
LTC, painful conditions was the second most common 
LTC. We have found no evidence to support any associa-
tions between EHR different patterns or counts of multi-
morbidity and HbA1c. While it is important for clinicians 
to consider the impact of multimorbidity in people with 
T2D, the reasons for the increased mortality observed 
elsewhere remain unclear and at present are not clearly 
linked to HbA1c. Our study demonstrates the use of 
routinely collected real- world clinical data in research, 
and highlights opportunities to enhance its value in 
the study of multimorbidity. Better understanding of 
the implications of multimorbidity in people with T2D, 
for example, focusing on the importance of common 
comorbid conditions such as painful conditions will allow 
more effective tailored care for people with T2D.
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of the data and the accuracy of data analyses. All authors assisted with iterative 
Predictor variables
Prevalence N 
(%)
Non- adjusted Adjusted*
Mean 
difference in 
HbA1c (SE) 95% CI P value
Mean 
difference in 
HbA1c (SE) 95% CI P value
Depression+thyroid disorders 2396 (3.4) 0.01 (0.03) −0.05 to 0.07 0.681 −0.01 (0.03) −0.06 to 0.05 0.815
Anxiety+thyroid disorders 2152 (3.1) 0.02 (0.03) −0.04 to 0.08 0.533 −0.01 (0.03) −0.06 to 0.05 0.847
Cancer+asthma 2040 (2.9) −0.02 (0.03) −0.08 to 0.04 0.516 −0.03 (0.03) −0.08 to 0.04 0.496
Coronary heart disease+asthma 2002 (2.9) 0.01 (0.03) −0.06 to 0.07 0.818 0.01 (0.03) −0.05 to 0.07 0.771
Psoriasis/eczema+thyroid 
disorders
1986 (2.9) 0.04 (0.03) −0.02 to 0.11 0.215 0.04 (0.03) −0.02 to 0.10 0.250
Cancer+thyroid disorders 1720 (2.5) 0.04 (0.04) −0.03 to 0.11 0.241 0.01 (0.03) −0.05 to 0.08 0.712
Asthma+thyroid disorders 1551 (2.2) 0.00 (0.04) −0.07 to 0.07 0.963 0.00 (0.03) −0.07 to 0.07 0.972
Coronary heart disease+thyroid 
disorders
1400 (2.0) 0.06 (0.04) −0.01 to 0.14 0.109 0.07 (0.04) 0.00 to 0.14 0.065
*Adjusting for age, sex, SEIFA, smoking status, and number of diabetes medication. All covariates were treated as fixed effects and the general 
practice as a random effect to allow for the correlation of HbA1c within each practice.
HbA1c, glycated haemoglobin; SEIFA, Socio- Economic Indexes for Areas.
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Supplementary Document 1 
Table S1. List of chronic conditions considered for multimorbidity count 
Chronic conditions grouping Conditions included 
Concordant conditions 
1. Hypertension Hypertension 
Essential hypertension 
2. Coronary heart Disease Heart attack/Myocardial infarction 
Angina 
3. Peripheral vascular disease Peripheral vascular disease 
Leg claudication/intermittent claudication 
4. Chronic kidney disease Polycystic kidney 
Diabetic nephropathy 
Renal/kidney failure 
Renal failure requiring dialysis 
Renal failure not requiring dialysis 
Kidney nephropathy 
Immunoglobulin A (IgA) nephropathy 
5. Stroke/Transient Ischaemic Attack (TIA) Stroke 
TIA 
Subarachnoid haemorrhage 
Brain haemorrhage 
Ischaemic stroke 
6. Diabetic retinopathy Diabetic eye disease 
7. Diabetic neuropathy Diabetic neuropathy/ulcers 
8. Atrial fibrillation Atrial fibrillation 
9. Heart failure Cardiomyopathy 
Hypertrophic cardiomyopathy 
Heart failure/pulmonary oedema 
Discordant conditions 
10. Depression Depression 
Postnatal depression 
11. Painful conditions Back pain 
Joint pain 
Headaches (not migraine) 
Sciatica 
Plantar fasciitis 
Carpal tunnel syndrome 
Fibromyalgia 
Arthritis 
Shingles 
Disc problem 
Prolapsed disc/slipped disc 
Spine arthritis/spondylitis 
Ankylosing spondylitis 
Back problem 
Osteoarthritis 
Gout 
Cervical spondylosis 
Trigeminal neuralgia 
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Disc degeneration 
Trapped nerve/compressed nerve 
12. Asthma Asthma 
13. Dyspepsia Gastro-oesophageal reflux (GORD)/gastric 
reflux 
Oesophagitis /Barrett's oesophagus 
Gastric stomach ulcers 
Gastric erosions/gastritis 
Duodenal ulcer 
Dyspepsia/indigestion 
Hiatus hernia 
Helicobacter pylori 
14. Thyroid disorders Thyroid problem (not cancer) 
Hyperthyroidism/thyrotoxicosis 
Hypothyroidism/myxoedema 
Grave’s disease 
Thyroid goitre 
Thyroiditis 
15. Rheumatoid arthritis and other 
connective tissue disorders 
Myositis/myopathy 
Systemic Lupus Erythematosus 
Connective tissue disorder 
Sjogrens syndrome/sicca syndrome 
Dermatopolymyositis 
Scleroderma/systemic sclerosis 
Rheumatoid arthritis 
Psoriatic arthropathy 
Dermatomyositis 
Polymyositis 
Polymyalgia Rheumatica 
Malabsorption/coeliac disease 
16. Chronic Obstructive Pulmonary Disease 
(COPD) 
COPD/chronic obstructive airways disease 
Emphysema/chronic bronchitis 
Emphysema 
17. Irritable bowel syndrome Irritable bowel syndrome 
18. Cancer Lifetime diagnosis 
19. Alcohol problems Alcohol dependency 
Alcoholic liver disease/alcoholic cirrhosis 
20. Other psychoactive substance misuse Opioid dependency 
Other substance abuse/dependency 
21. Constipation Constipation 
22. Diverticular disease Diverticular disease 
Diverticulitis 
23. Prostate disorders Prostate problem (not cancer) 
Enlarged prostate 
Benign prostatic hypertrophy 
24. Glaucoma Glaucoma 
25. Epilepsy Epilepsy 
26. Dementia Dementia 
Alzheimer’s disease 
Cognitive impairment 
27. Schizophrenia/bipolar disorder Schizophrenia 
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Mania/ 
Bipolar disorder 
Manic depression 
28. Psoriasis/eczema Eczema 
Dermatitis 
Psoriasis 
29. Inflammatory bowel disease Inflammatory Bowel Disease 
Crohn’s disease 
Ulcerative colitis 
30. Migraine Migraine 
31. Chronic sinusitis Chronic sinusitis 
32. Anorexia/bulimia Anorexia 
Bulimia 
Other eating disorders 
33. Bronchiectasis Bronchiectasis 
34. Parkinson’s disease Parkinson’s disease 
35. Multiple sclerosis Multiple sclerosis 
36. Viral hepatitis Infective/viral hepatitis 
Hepatitis B 
Hepatitis C 
Hepatitis D 
Hepatitis E 
37. Chronic liver disease Oesophageal varices 
Non infective hepatitis 
Liver failure/cirrhosis 
Primary biliary cirrhosis 
38. Osteoporosis Osteoporosis 
39. Chronic fatigue syndrome Chronic fatigue syndrome 
40. Endometriosis Endometriosis 
41. Meniere’s disease Meniere’s disease 
42. Pernicious anaemia Pernicious anaemia 
43. Polycystic ovary Polycystic ovary 
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Table S2. Sensitivity analysis - multivariable linear regression model: Relationship between HbA1c(%) and multimorbidity in participants with type 2 
diabetes. 
 
 Non-adjusted Adjusted* 
Predictor variables Mean 
difference in 
HbA1c (SE) 
95% CI p Mean 
difference in 
HbA1c (SE) 
95% CI p 
Participants with HbA1c > 7%       
Categories of diabetes and multimorbidities       
   Diabetes present and no chronic conditions (reference)       
   Diabetes present and 1 chronic condition 0.00 (0.03) -0.07, 0.07 0.995 0.00 (0.04) -0.07, 0.07 0.915 
   Diabetes present and 2 chronic conditions -0.03 (0.03) -0.10, 0.03 0.322 -0.03 (0.03) -0.10, 0.04 0.359 
   Diabetes present and 3 chronic conditions 0.02 (0.03) -0.05, 0.08 0.624 0.02 (0.03) -0.05, 0.09 0.553 
   Diabetes present and 4 or more chronic conditions 0.01 (0.03) -0.05, 0.07 0.726 0.02 (0.03) -0.04, 0.07 0.592 
Categories of diabetes and concordant conditions       
   Diabetes present and no chronic conditions (reference)       
   Diabetes present and 1 concordant condition 0.02 (0.02) -0.02, 0.05 0.422 0.02 (0.02) -0.02, 0.06 0.315 
   Diabetes present and 2 concordant conditions 0.02 (0.03) -0.03, 0.07 0.338 0.04 (0.02) -0.01, 0.09 0.122 
   Diabetes present and 3 concordant conditions -0.02 (0.03) -0.08, 0.05 0.609 -0.02 (0.03) -0.08, 0.05 0.650 
   Diabetes present and 4 or more concordant conditions 0.03 (0.04) -0.056, 0.11 0.513 0.03 (0.04) -0.05, 0.11 0.472 
Categories of diabetes and discordant conditions       
   Diabetes present and no chronic conditions (reference)       
   Diabetes present and 1 discordant condition -0.05 (0.03) -0.10, 0.00 0.063 -0.07 (0.03) -0.12, 0.02 0.012 
   Diabetes present and 2 discordant conditions -0.02 (0.03) -0.07, 0.04 0.540 -0.03 (0.03) -0.08, 0.03 0.293 
   Diabetes present and 3 discordant conditions 0.02 (0.03) -0.04, 0.07 0.572 0.00 (0.03) -0.06, 0.06 0.993 
   Diabetes present and 4 or more discordant conditions 0.00 (0.03) -0.05, 0.05 0.879 -0.00 (0.03) -0.05, 0.05 0.970 
Participants with HbA1c ≤ 7%       
Categories of diabetes and multimorbidities       
   Diabetes present and no chronic conditions (reference)       
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   Diabetes present and 1 chronic condition 0.01 (0.01) -0.02, 0.03 0.586 0.00 (0.01) -0.02, 0.02 0.929 
   Diabetes present and 2 chronic conditions 0.01 (0.01) -0.01, 0.03 0.317 0.01 (0.01) -0.01, 0.03 0.562 
   Diabetes present and 3 chronic conditions -0.01 (0.01) -0.03, 0.01 0.548 -0.01 (0.01) -0.03, 0.01 0.277 
   Diabetes present and 4 or more chronic conditions 0.00 (0.01) -0.02, 0.02 0.771 0.00 (0.01) -0.02, 0.02 0.978 
Categories of diabetes and concordant conditions       
   Diabetes present and no chronic conditions (reference)       
   Diabetes present and 1 concordant condition 0.01 (0.01) 0.00, 0.02 0.233 0.01 (0.01) 0.00, 0.02 0.232 
   Diabetes present and 2 concordant conditions 0.01 (0.01) 0.00, 0.03 0.076 0.01 (0.01) 0.00, 0.03 0.136 
   Diabetes present and 3 concordant conditions 0.01 (0.01) -0.01, 0.03 0.480 0.00 (0.01) -0.02, 0.02 0.855 
   Diabetes present and 4 or more concordant conditions 0.00 (0.01) -0.03, 0.02 0.939 0.00 (0.01) -0.03, 0.02 0.919 
Categories of diabetes and discordant conditions       
   Diabetes present and no chronic conditions (reference)       
   Diabetes present and 1 discordant condition 0.01 (0.01) -0.01, 0.02 0.448 0.00 (0.01) -0.02, 0.02 0.921 
   Diabetes present and 2 discordant conditions -0.02 (0.01) -0.03, 0.00 0.027 -0.02 (0.01) -0.04, 0.00 0.020 
   Diabetes present and 3 discordant conditions -0.01 (0.01) -0.02, 0.01 0.495 -0.01 (0.01) -0.02, 0.01 0.462 
   Diabetes present and 4 or more discordant conditions 0.00 (0.01) -0.02, 0.01 0.825 0.00 (0.01) -0.02, 0.01 0.628 
SE: Standard error 
*Adjusting for age, sex, SEIFA, smoking status, and number of diabetes medication. All co-variates were treated as fixed effects and the general practice as a 
random effect to allow for the correlation of HbA1c within each practice. 
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Table S1. List of chronic conditions considered for multimorbidity count 
Chronic conditions grouping Conditions included 
Concordant conditions 
1. Hypertension Hypertension 
Essential hypertension 
2. Coronary heart Disease Heart attack/Myocardial infarction 
Angina 
3. Peripheral vascular disease Peripheral vascular disease 
Leg claudication/intermittent claudication 
4. Chronic kidney disease Polycystic kidney 
Diabetic nephropathy 
Renal/kidney failure 
Renal failure requiring dialysis 
Renal failure not requiring dialysis 
Kidney nephropathy 
Immunoglobulin A (IgA) nephropathy 
5. Stroke/Transient Ischaemic Attack (TIA) Stroke 
TIA 
Subarachnoid haemorrhage 
Brain haemorrhage 
Ischaemic stroke 
6. Diabetic retinopathy Diabetic eye disease 
7. Diabetic neuropathy Diabetic neuropathy/ulcers 
8. Atrial fibrillation Atrial fibrillation 
9. Heart failure Cardiomyopathy 
Hypertrophic cardiomyopathy 
Heart failure/pulmonary oedema 
Discordant conditions 
10. Depression Depression 
Postnatal depression 
11. Painful conditions Back pain 
Joint pain 
Headaches (not migraine) 
Sciatica 
Plantar fasciitis 
Carpal tunnel syndrome 
Fibromyalgia 
Arthritis 
Shingles 
Disc problem 
Prolapsed disc/slipped disc 
Spine arthritis/spondylitis 
Ankylosing spondylitis 
Back problem 
Osteoarthritis 
Gout 
Cervical spondylosis 
Trigeminal neuralgia 
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Disc degeneration 
Trapped nerve/compressed nerve 
12. Asthma Asthma 
13. Dyspepsia Gastro-oesophageal reflux (GORD)/gastric 
reflux 
Oesophagitis /Barrett's oesophagus 
Gastric stomach ulcers 
Gastric erosions/gastritis 
Duodenal ulcer 
Dyspepsia/indigestion 
Hiatus hernia 
Helicobacter pylori 
14. Thyroid disorders Thyroid problem (not cancer) 
Hyperthyroidism/thyrotoxicosis 
Hypothyroidism/myxoedema 
Grave’s disease 
Thyroid goitre 
Thyroiditis 
15. Rheumatoid arthritis and other 
connective tissue disorders 
Myositis/myopathy 
Systemic Lupus Erythematosus 
Connective tissue disorder 
Sjogrens syndrome/sicca syndrome 
Dermatopolymyositis 
Scleroderma/systemic sclerosis 
Rheumatoid arthritis 
Psoriatic arthropathy 
Dermatomyositis 
Polymyositis 
Polymyalgia Rheumatica 
Malabsorption/coeliac disease 
16. Chronic Obstructive Pulmonary Disease 
(COPD) 
COPD/chronic obstructive airways disease 
Emphysema/chronic bronchitis 
Emphysema 
17. Irritable bowel syndrome Irritable bowel syndrome 
18. Cancer Lifetime diagnosis 
19. Alcohol problems Alcohol dependency 
Alcoholic liver disease/alcoholic cirrhosis 
20. Other psychoactive substance misuse Opioid dependency 
Other substance abuse/dependency 
21. Constipation Constipation 
22. Diverticular disease Diverticular disease 
Diverticulitis 
23. Prostate disorders Prostate problem (not cancer) 
Enlarged prostate 
Benign prostatic hypertrophy 
24. Glaucoma Glaucoma 
25. Epilepsy Epilepsy 
26. Dementia Dementia 
Alzheimer’s disease 
Cognitive impairment 
27. Schizophrenia/bipolar disorder Schizophrenia 
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Mania/ 
Bipolar disorder 
Manic depression 
28. Psoriasis/eczema Eczema 
Dermatitis 
Psoriasis 
29. Inflammatory bowel disease Inflammatory Bowel Disease 
Crohn’s disease 
Ulcerative colitis 
30. Migraine Migraine 
31. Chronic sinusitis Chronic sinusitis 
32. Anorexia/bulimia Anorexia 
Bulimia 
Other eating disorders 
33. Bronchiectasis Bronchiectasis 
34. Parkinson’s disease Parkinson’s disease 
35. Multiple sclerosis Multiple sclerosis 
36. Viral hepatitis Infective/viral hepatitis 
Hepatitis B 
Hepatitis C 
Hepatitis D 
Hepatitis E 
37. Chronic liver disease Oesophageal varices 
Non infective hepatitis 
Liver failure/cirrhosis 
Primary biliary cirrhosis 
38. Osteoporosis Osteoporosis 
39. Chronic fatigue syndrome Chronic fatigue syndrome 
40. Endometriosis Endometriosis 
41. Meniere’s disease Meniere’s disease 
42. Pernicious anaemia Pernicious anaemia 
43. Polycystic ovary Polycystic ovary 
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Table S2. Sensitivity analysis - multivariable linear regression model: Relationship between HbA1c(%) and multimorbidity in participants with type 2 
diabetes. 
 
 Non-adjusted Adjusted* 
Predictor variables Mean 
difference in 
HbA1c (SE) 
95% CI p Mean 
difference in 
HbA1c (SE) 
95% CI p 
Participants with HbA1c > 7%       
Categories of diabetes and multimorbidities       
   Diabetes present and no chronic conditions (reference)       
   Diabetes present and 1 chronic condition 0.00 (0.03) -0.07, 0.07 0.995 0.00 (0.04) -0.07, 0.07 0.915 
   Diabetes present and 2 chronic conditions -0.03 (0.03) -0.10, 0.03 0.322 -0.03 (0.03) -0.10, 0.04 0.359 
   Diabetes present and 3 chronic conditions 0.02 (0.03) -0.05, 0.08 0.624 0.02 (0.03) -0.05, 0.09 0.553 
   Diabetes present and 4 or more chronic conditions 0.01 (0.03) -0.05, 0.07 0.726 0.02 (0.03) -0.04, 0.07 0.592 
Categories of diabetes and concordant conditions       
   Diabetes present and no chronic conditions (reference)       
   Diabetes present and 1 concordant condition 0.02 (0.02) -0.02, 0.05 0.422 0.02 (0.02) -0.02, 0.06 0.315 
   Diabetes present and 2 concordant conditions 0.02 (0.03) -0.03, 0.07 0.338 0.04 (0.02) -0.01, 0.09 0.122 
   Diabetes present and 3 concordant conditions -0.02 (0.03) -0.08, 0.05 0.609 -0.02 (0.03) -0.08, 0.05 0.650 
   Diabetes present and 4 or more concordant conditions 0.03 (0.04) -0.056, 0.11 0.513 0.03 (0.04) -0.05, 0.11 0.472 
Categories of diabetes and discordant conditions       
   Diabetes present and no chronic conditions (reference)       
   Diabetes present and 1 discordant condition -0.05 (0.03) -0.10, 0.00 0.063 -0.07 (0.03) -0.12, 0.02 0.012 
   Diabetes present and 2 discordant conditions -0.02 (0.03) -0.07, 0.04 0.540 -0.03 (0.03) -0.08, 0.03 0.293 
   Diabetes present and 3 discordant conditions 0.02 (0.03) -0.04, 0.07 0.572 0.00 (0.03) -0.06, 0.06 0.993 
   Diabetes present and 4 or more discordant conditions 0.00 (0.03) -0.05, 0.05 0.879 -0.00 (0.03) -0.05, 0.05 0.970 
Participants with HbA1c ≤ 7%       
Categories of diabetes and multimorbidities       
   Diabetes present and no chronic conditions (reference)       
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   Diabetes present and 1 chronic condition 0.01 (0.01) -0.02, 0.03 0.586 0.00 (0.01) -0.02, 0.02 0.929 
   Diabetes present and 2 chronic conditions 0.01 (0.01) -0.01, 0.03 0.317 0.01 (0.01) -0.01, 0.03 0.562 
   Diabetes present and 3 chronic conditions -0.01 (0.01) -0.03, 0.01 0.548 -0.01 (0.01) -0.03, 0.01 0.277 
   Diabetes present and 4 or more chronic conditions 0.00 (0.01) -0.02, 0.02 0.771 0.00 (0.01) -0.02, 0.02 0.978 
Categories of diabetes and concordant conditions       
   Diabetes present and no chronic conditions (reference)       
   Diabetes present and 1 concordant condition 0.01 (0.01) 0.00, 0.02 0.233 0.01 (0.01) 0.00, 0.02 0.232 
   Diabetes present and 2 concordant conditions 0.01 (0.01) 0.00, 0.03 0.076 0.01 (0.01) 0.00, 0.03 0.136 
   Diabetes present and 3 concordant conditions 0.01 (0.01) -0.01, 0.03 0.480 0.00 (0.01) -0.02, 0.02 0.855 
   Diabetes present and 4 or more concordant conditions 0.00 (0.01) -0.03, 0.02 0.939 0.00 (0.01) -0.03, 0.02 0.919 
Categories of diabetes and discordant conditions       
   Diabetes present and no chronic conditions (reference)       
   Diabetes present and 1 discordant condition 0.01 (0.01) -0.01, 0.02 0.448 0.00 (0.01) -0.02, 0.02 0.921 
   Diabetes present and 2 discordant conditions -0.02 (0.01) -0.03, 0.00 0.027 -0.02 (0.01) -0.04, 0.00 0.020 
   Diabetes present and 3 discordant conditions -0.01 (0.01) -0.02, 0.01 0.495 -0.01 (0.01) -0.02, 0.01 0.462 
   Diabetes present and 4 or more discordant conditions 0.00 (0.01) -0.02, 0.01 0.825 0.00 (0.01) -0.02, 0.01 0.628 
SE: Standard error 
*Adjusting for age, sex, SEIFA, smoking status, and number of diabetes medication. All co-variates were treated as fixed effects and the general practice as a 
random effect to allow for the correlation of HbA1c within each practice. 
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